Search Results for: Pulmonary

5304 interactions found:

Symbols Name 1 Name 2
Pathways 1
Pathways 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
ABCA1 and SNTB2 ATP binding cassette subfamily A member 1 syntrophin beta 2
  • PPARA activates gene expression
  • Defective ABCA1 causes Tangier disease
  • HDL assembly
  • NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux
  • ATP
  • Glyburide
  • Probucol
  • Tangier disease
  • Hypoalphalipoproteinemia
ABCA1 and SDHB ATP binding cassette subfamily A member 1 succinate dehydrogenase complex iron sulfur subunit B
  • PPARA activates gene expression
  • Defective ABCA1 causes Tangier disease
  • HDL assembly
  • NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux
  • Respiratory electron transport
  • Citric acid cycle (TCA cycle)
  • ATP
  • Glyburide
  • Probucol
  • Succinic acid
  • 2-Hexyloxy-6-Hydroxymethyl-Tetrahydro-Pyran-3,4,5-Triol
  • UBIQUINONE-1
  • Tangier disease
  • Hypoalphalipoproteinemia
ABCA1 and PRKACA ATP binding cassette subfamily A member 1 protein kinase cAMP-activated catalytic subunit alpha
  • PPARA activates gene expression
  • Defective ABCA1 causes Tangier disease
  • HDL assembly
  • NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux
  • PKA-mediated phosphorylation of CREB
  • PKA-mediated phosphorylation of key metabolic factors
  • Triglyceride catabolism
  • PKA activation
  • PKA activation in glucagon signalling
  • DARPP-32 events
  • Regulation of PLK1 Activity at G2/M Transition
  • Loss of Nlp from mitotic centrosomes
  • Recruitment of mitotic centrosome proteins and complexes
  • Loss of proteins required for interphase microtubule organization from the centrosome
  • Recruitment of NuMA to mitotic centrosomes
  • Glucagon-like Peptide-1 (GLP1) regulates insulin secretion
  • Glucagon-like Peptide-1 (GLP1) regulates insulin secretion
  • Rap1 signalling
  • Regulation of insulin secretion
  • Vasopressin regulates renal water homeostasis via Aquaporins
  • VEGFA-VEGFR2 Pathway
  • CREB1 phosphorylation through the activation of Adenylate Cyclase
  • CREB1 phosphorylation through the activation of Adenylate Cyclase
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • Ion homeostasis
  • Degradation of GLI1 by the proteasome
  • Degradation of GLI2 by the proteasome
  • GLI3 is processed to GLI3R by the proteasome
  • Hedgehog 'off' state
  • Anchoring of the basal body to the plasma membrane
  • CD209 (DC-SIGN) signaling
  • MAPK6/MAPK4 signaling
  • RET signaling
  • AURKA Activation by TPX2
  • HDL assembly
  • ROBO receptors bind AKAP5
  • Loss of phosphorylation of MECP2 at T308
  • Regulation of MECP2 expression and activity
  • Regulation of glycolysis by fructose 2,6-bisphosphate metabolism
  • ADORA2B mediated anti-inflammatory cytokines production
  • ADORA2B mediated anti-inflammatory cytokines production
  • FCGR3A-mediated IL10 synthesis
  • FCGR3A-mediated IL10 synthesis
  • Factors involved in megakaryocyte development and platelet production
  • ATP
  • Glyburide
  • Probucol
  • Pentanal
  • Balanol Analog 2
  • Balanol Analog 8
  • Phosphonothreonine
  • Balanol Analog 1
  • 3,5-Diiodotyrosine
  • Balanol
  • Dexfosfoserine
  • S,S-(2-Hydroxyethyl)Thiocysteine
  • Hydroxyfasudil
  • (1S)-2-(1H-INDOL-3-YL)-1-{[(5-ISOQUINOLIN-6-YLPYRIDIN-3-YL)OXY]METHYL}ETHYLAMINE
  • (2S)-1-{[5-(1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}-3-[(7AS)-7AH-INDOL-3-YL]PROPAN-2-AMINE
  • (1S)-2-(1H-INDOL-3-YL)-1-[({5-[(E)-2-PYRIDIN-4-YLVINYL]PYRIDIN-3-YL}OXY)METHYL]ETHYLAMINE
  • (2S)-1-(6H-INDOL-3-YL)-3-{[5-(7H-PYRAZOLO[3,4-C]PYRIDIN-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE
  • (1S)-1-(1H-INDOL-3-YLMETHYL)-2-(2-PYRIDIN-4-YL-[1,7]NAPHTYRIDIN-5-YLOXY)-EHYLAMINE
  • N-[(1S)-2-AMINO-1-(2,4-DICHLOROBENZYL)ETHYL]-5-[2-(METHYLAMINO)PYRIMIDIN-4-YL]THIOPHENE-2-CARBOXAMIDE
  • 3-(1H-indol-3-yl)-4-{1-[2-(1-methylpyrrolidin-2-yl)ethyl]-1H-indol-3-yl}-1H-pyrrole-2,5-dione
  • (4R,2S)-5'-(4-(4-CHLOROBENZYLOXY)PYRROLIDIN-2-YLMETHANESULFONYL)ISOQUINOLINE
  • N-METHYL-1-[4-(9H-PURIN-6-YL)PHENYL]METHANAMINE
  • (S)-1-PHENYL-1-[4-(9H-PURIN-6-YL)PHENYL]METHANAMINE
  • 6-{4-[4-(4-CHLOROPHENYL)PIPERIDIN-4-YL]PHENYL}-9H-PURINE
  • (2R)-2-(4-chlorophenyl)-2-[4-(1H-pyrazol-4-yl)phenyl]ethanamine
  • (2S)-2-(4-chlorophenyl)-2-[4-(1H-pyrazol-4-yl)phenyl]ethanamine
  • 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE
  • (2R)-2-(4-CHLOROPHENYL)-2-PHENYLETHANAMINE
  • (S)-2-METHYL-1-[(4-METHYL-5-ISOQUINOLINE)SULFONYL]-HOMOPIPERAZINE
  • ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE
  • N-[2-(4-BROMOCINNAMYLAMINO)ETHYL]-5-ISOQUINOLINE SULFONAMIDE
  • 5-(2-methylpiperazine-1-sulfonyl)isoquinoline
  • N-[2-(METHYLAMINO)ETHYL]-5-ISOQUINOLINESULFONAMIDE
  • 2-[4-(3-METHYL-1H-PYRAZOL-4-YL)PHENYL]ETHANAMINE
  • (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE
  • 3-pyridin-4-yl-1H-indazole
  • 5-benzyl-1,3-thiazol-2-amine
  • 1-[4-(4-chlorophenyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine
  • 1-[4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine
  • 4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-aminium
  • Fasudil
  • Myristic acid
  • (2S)-1-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}-3-PHENYLPROPAN-2-AMINE
  • 3-PYRIDIN-4-YL-2,4-DIHYDRO-INDENO[1,2-.C.] PYRAZOLE
  • (R)-TRANS-4-(1-AMINOETHYL)-N-(4-PYRIDYL) CYCLOHEXANECARBOXAMIDE
  • Ellagic Acid
  • Tangier disease
  • Hypoalphalipoproteinemia
ABCA1 and ERP44 ATP binding cassette subfamily A member 1 endoplasmic reticulum protein 44
  • PPARA activates gene expression
  • Defective ABCA1 causes Tangier disease
  • HDL assembly
  • NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux
  • Neutrophil degranulation
  • ATP
  • Glyburide
  • Probucol
  • Tangier disease
  • Hypoalphalipoproteinemia
ABCA1 and PDLIM4 ATP binding cassette subfamily A member 1 PDZ and LIM domain 4
  • PPARA activates gene expression
  • Defective ABCA1 causes Tangier disease
  • HDL assembly
  • NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux
  • ATP
  • Glyburide
  • Probucol
  • Tangier disease
  • Hypoalphalipoproteinemia
ABL1 and MAPT ABL proto-oncogene 1, non-receptor tyrosine kinase microtubule associated protein tau
  • Regulation of actin dynamics for phagocytic cup formation
  • Role of ABL in ROBO-SLIT signaling
  • Role of ABL in ROBO-SLIT signaling
  • Myogenesis
  • Myogenesis
  • RHO GTPases Activate WASPs and WAVEs
  • HDR through Single Strand Annealing (SSA)
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
  • Cyclin D associated events in G1
  • RUNX1 regulates transcription of genes involved in differentiation of HSCs
  • RUNX2 regulates osteoblast differentiation
  • FCGR3A-mediated phagocytosis
  • Factors involved in megakaryocyte development and platelet production
  • Caspase-mediated cleavage of cytoskeletal proteins
  • ATP
  • Imatinib
  • Dasatinib
  • N-[4-Methyl-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino]Phenyl]-3-Pyridinecarboxamide
  • Nilotinib
  • XL228
  • Bosutinib
  • 2-{[(6-OXO-1,6-DIHYDROPYRIDIN-3-YL)METHYL]AMINO}-N-[4-PROPYL-3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE
  • 1-[4-(PYRIDIN-4-YLOXY)PHENYL]-3-[3-(TRIFLUOROMETHYL)PHENYL]UREA
  • Myristic acid
  • 6-(2,6-DICHLOROPHENYL)-2-{[3-(HYDROXYMETHYL)PHENYL]AMINO}-8-METHYLPYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE
  • 5-[3-(2-METHOXYPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-5-YL]-N,N-DIMETHYLPYRIDINE-3-CARBOXAMIDE
  • 2-amino-5-[3-(1-ethyl-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,N-dimethylbenzamide
  • Regorafenib
  • Ponatinib
  • Brigatinib
  • Radotinib
  • Lansoprazole
  • Astemizole
  • Paclitaxel
  • Docetaxel
  • Chronic myeloid leukemia (CML)
  • Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)
  • Amyotrophic lateral sclerosis (ALS); Lou Gehrig's disease
  • Frontotemporal lobar degeneration (FTLD), including: Pick disease of brain; Frontotemporal dementia (FTD); Ubiquitin-positive frontotemporal dementia (UP-FTD); Progressive supranuclear palsy type 1 (PSNP1); Inclusion body myopathy with early-onset paget disease and frontotemporal dementia (IBMPFD); Frontotemporal dementia, chromosome 3-linked (FTD3)
  • Progressive supranuclear palsy (PSP); Steele-Richardson-Olszewski syndrome
ABL1 and ROBO1 ABL proto-oncogene 1, non-receptor tyrosine kinase roundabout guidance receptor 1
  • Regulation of actin dynamics for phagocytic cup formation
  • Role of ABL in ROBO-SLIT signaling
  • Role of ABL in ROBO-SLIT signaling
  • Myogenesis
  • Myogenesis
  • RHO GTPases Activate WASPs and WAVEs
  • HDR through Single Strand Annealing (SSA)
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
  • Cyclin D associated events in G1
  • RUNX1 regulates transcription of genes involved in differentiation of HSCs
  • RUNX2 regulates osteoblast differentiation
  • FCGR3A-mediated phagocytosis
  • Factors involved in megakaryocyte development and platelet production
  • Netrin-1 signaling
  • Signaling by ROBO receptors
  • Signaling by ROBO receptors
  • Activation of RAC1
  • Regulation of commissural axon pathfinding by SLIT and ROBO
  • Regulation of commissural axon pathfinding by SLIT and ROBO
  • Inactivation of CDC42 and RAC1
  • Role of ABL in ROBO-SLIT signaling
  • Role of ABL in ROBO-SLIT signaling
  • SLIT2:ROBO1 increases RHOA activity
  • Regulation of cortical dendrite branching
  • Regulation of expression of SLITs and ROBOs
  • Regulation of expression of SLITs and ROBOs
  • ATP
  • Imatinib
  • Dasatinib
  • N-[4-Methyl-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino]Phenyl]-3-Pyridinecarboxamide
  • Nilotinib
  • XL228
  • Bosutinib
  • 2-{[(6-OXO-1,6-DIHYDROPYRIDIN-3-YL)METHYL]AMINO}-N-[4-PROPYL-3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE
  • 1-[4-(PYRIDIN-4-YLOXY)PHENYL]-3-[3-(TRIFLUOROMETHYL)PHENYL]UREA
  • Myristic acid
  • 6-(2,6-DICHLOROPHENYL)-2-{[3-(HYDROXYMETHYL)PHENYL]AMINO}-8-METHYLPYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE
  • 5-[3-(2-METHOXYPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-5-YL]-N,N-DIMETHYLPYRIDINE-3-CARBOXAMIDE
  • 2-amino-5-[3-(1-ethyl-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,N-dimethylbenzamide
  • Regorafenib
  • Ponatinib
  • Brigatinib
  • Radotinib
  • Chronic myeloid leukemia (CML)
  • Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)
ABL1 and SFN ABL proto-oncogene 1, non-receptor tyrosine kinase stratifin
  • Regulation of actin dynamics for phagocytic cup formation
  • Role of ABL in ROBO-SLIT signaling
  • Role of ABL in ROBO-SLIT signaling
  • Myogenesis
  • Myogenesis
  • RHO GTPases Activate WASPs and WAVEs
  • HDR through Single Strand Annealing (SSA)
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
  • Cyclin D associated events in G1
  • RUNX1 regulates transcription of genes involved in differentiation of HSCs
  • RUNX2 regulates osteoblast differentiation
  • FCGR3A-mediated phagocytosis
  • Factors involved in megakaryocyte development and platelet production
  • Activation of BAD and translocation to mitochondria
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • RHO GTPases activate PKNs
  • TP53 Regulates Metabolic Genes
  • TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
  • Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
  • Regulation of localization of FOXO transcription factors
  • ATP
  • Imatinib
  • Dasatinib
  • N-[4-Methyl-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino]Phenyl]-3-Pyridinecarboxamide
  • Nilotinib
  • XL228
  • Bosutinib
  • 2-{[(6-OXO-1,6-DIHYDROPYRIDIN-3-YL)METHYL]AMINO}-N-[4-PROPYL-3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE
  • 1-[4-(PYRIDIN-4-YLOXY)PHENYL]-3-[3-(TRIFLUOROMETHYL)PHENYL]UREA
  • Myristic acid
  • 6-(2,6-DICHLOROPHENYL)-2-{[3-(HYDROXYMETHYL)PHENYL]AMINO}-8-METHYLPYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE
  • 5-[3-(2-METHOXYPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-5-YL]-N,N-DIMETHYLPYRIDINE-3-CARBOXAMIDE
  • 2-amino-5-[3-(1-ethyl-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,N-dimethylbenzamide
  • Regorafenib
  • Ponatinib
  • Brigatinib
  • Radotinib
  • Chronic myeloid leukemia (CML)
  • Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)
ABL1 and BCAR1 ABL proto-oncogene 1, non-receptor tyrosine kinase BCAR1 scaffold protein, Cas family member
  • Regulation of actin dynamics for phagocytic cup formation
  • Role of ABL in ROBO-SLIT signaling
  • Role of ABL in ROBO-SLIT signaling
  • Myogenesis
  • Myogenesis
  • RHO GTPases Activate WASPs and WAVEs
  • HDR through Single Strand Annealing (SSA)
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
  • Cyclin D associated events in G1
  • RUNX1 regulates transcription of genes involved in differentiation of HSCs
  • RUNX2 regulates osteoblast differentiation
  • FCGR3A-mediated phagocytosis
  • Factors involved in megakaryocyte development and platelet production
  • Downstream signal transduction
  • p130Cas linkage to MAPK signaling for integrins
  • VEGFA-VEGFR2 Pathway
  • VEGFA-VEGFR2 Pathway
  • PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
  • ATP
  • Imatinib
  • Dasatinib
  • N-[4-Methyl-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino]Phenyl]-3-Pyridinecarboxamide
  • Nilotinib
  • XL228
  • Bosutinib
  • 2-{[(6-OXO-1,6-DIHYDROPYRIDIN-3-YL)METHYL]AMINO}-N-[4-PROPYL-3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE
  • 1-[4-(PYRIDIN-4-YLOXY)PHENYL]-3-[3-(TRIFLUOROMETHYL)PHENYL]UREA
  • Myristic acid
  • 6-(2,6-DICHLOROPHENYL)-2-{[3-(HYDROXYMETHYL)PHENYL]AMINO}-8-METHYLPYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE
  • 5-[3-(2-METHOXYPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-5-YL]-N,N-DIMETHYLPYRIDINE-3-CARBOXAMIDE
  • 2-amino-5-[3-(1-ethyl-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,N-dimethylbenzamide
  • Regorafenib
  • Ponatinib
  • Brigatinib
  • Radotinib
  • Chronic myeloid leukemia (CML)
  • Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)
ABL1 and TERT ABL proto-oncogene 1, non-receptor tyrosine kinase telomerase reverse transcriptase
  • Regulation of actin dynamics for phagocytic cup formation
  • Role of ABL in ROBO-SLIT signaling
  • Role of ABL in ROBO-SLIT signaling
  • Myogenesis
  • Myogenesis
  • RHO GTPases Activate WASPs and WAVEs
  • HDR through Single Strand Annealing (SSA)
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
  • Cyclin D associated events in G1
  • RUNX1 regulates transcription of genes involved in differentiation of HSCs
  • RUNX2 regulates osteoblast differentiation
  • FCGR3A-mediated phagocytosis
  • Factors involved in megakaryocyte development and platelet production
  • Telomere Extension By Telomerase
  • Formation of the beta-catenin:TCF transactivating complex
  • ATP
  • Imatinib
  • Dasatinib
  • N-[4-Methyl-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino]Phenyl]-3-Pyridinecarboxamide
  • Nilotinib
  • XL228
  • Bosutinib
  • 2-{[(6-OXO-1,6-DIHYDROPYRIDIN-3-YL)METHYL]AMINO}-N-[4-PROPYL-3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE
  • 1-[4-(PYRIDIN-4-YLOXY)PHENYL]-3-[3-(TRIFLUOROMETHYL)PHENYL]UREA
  • Myristic acid
  • 6-(2,6-DICHLOROPHENYL)-2-{[3-(HYDROXYMETHYL)PHENYL]AMINO}-8-METHYLPYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE
  • 5-[3-(2-METHOXYPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-5-YL]-N,N-DIMETHYLPYRIDINE-3-CARBOXAMIDE
  • 2-amino-5-[3-(1-ethyl-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,N-dimethylbenzamide
  • Regorafenib
  • Ponatinib
  • Brigatinib
  • Radotinib
  • Zidovudine
  • Grn163l
  • Tertomotide
  • Chronic myeloid leukemia (CML)
  • Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)
  • Cri du chat syndrome; Cat cry syndrome; Chromosme 5p deletion syndrome
ABL1 and HCK ABL proto-oncogene 1, non-receptor tyrosine kinase HCK proto-oncogene, Src family tyrosine kinase
  • Regulation of actin dynamics for phagocytic cup formation
  • Role of ABL in ROBO-SLIT signaling
  • Role of ABL in ROBO-SLIT signaling
  • Myogenesis
  • Myogenesis
  • RHO GTPases Activate WASPs and WAVEs
  • HDR through Single Strand Annealing (SSA)
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
  • Cyclin D associated events in G1
  • RUNX1 regulates transcription of genes involved in differentiation of HSCs
  • RUNX2 regulates osteoblast differentiation
  • FCGR3A-mediated phagocytosis
  • Factors involved in megakaryocyte development and platelet production
  • Nef and signal transduction
  • FCGR activation
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • FLT3 Signaling
  • FCGR3A-mediated IL10 synthesis
  • FCGR3A-mediated phagocytosis
  • ATP
  • Imatinib
  • Dasatinib
  • N-[4-Methyl-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino]Phenyl]-3-Pyridinecarboxamide
  • Nilotinib
  • XL228
  • Bosutinib
  • 2-{[(6-OXO-1,6-DIHYDROPYRIDIN-3-YL)METHYL]AMINO}-N-[4-PROPYL-3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE
  • 1-[4-(PYRIDIN-4-YLOXY)PHENYL]-3-[3-(TRIFLUOROMETHYL)PHENYL]UREA
  • Myristic acid
  • 6-(2,6-DICHLOROPHENYL)-2-{[3-(HYDROXYMETHYL)PHENYL]AMINO}-8-METHYLPYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE
  • 5-[3-(2-METHOXYPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-5-YL]-N,N-DIMETHYLPYRIDINE-3-CARBOXAMIDE
  • 2-amino-5-[3-(1-ethyl-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,N-dimethylbenzamide
  • Regorafenib
  • Ponatinib
  • Brigatinib
  • Radotinib
  • 1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
  • Phosphonotyrosine
  • Quercetin
  • Bosutinib
  • Chronic myeloid leukemia (CML)
  • Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)
ABL2 and FBXO38 ABL proto-oncogene 2, non-receptor tyrosine kinase F-box protein 38
  • Role of ABL in ROBO-SLIT signaling
  • Role of ABL in ROBO-SLIT signaling
  • ATP
  • Dasatinib
  • XL228
  • 5-AMINO-3-{[4-(AMINOSULFONYL)PHENYL]AMINO}-N-(2,6-DIFLUOROPHENYL)-1H-1,2,4-TRIAZOLE-1-CARBOTHIOAMIDE
ABL2 and HCK ABL proto-oncogene 2, non-receptor tyrosine kinase HCK proto-oncogene, Src family tyrosine kinase
  • Role of ABL in ROBO-SLIT signaling
  • Role of ABL in ROBO-SLIT signaling
  • Nef and signal transduction
  • FCGR activation
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • FLT3 Signaling
  • FCGR3A-mediated IL10 synthesis
  • FCGR3A-mediated phagocytosis
  • ATP
  • Dasatinib
  • XL228
  • 5-AMINO-3-{[4-(AMINOSULFONYL)PHENYL]AMINO}-N-(2,6-DIFLUOROPHENYL)-1H-1,2,4-TRIAZOLE-1-CARBOTHIOAMIDE
  • 1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
  • Phosphonotyrosine
  • Quercetin
  • Bosutinib
ACLY and KLHL25 ATP citrate lyase kelch like family member 25
  • ChREBP activates metabolic gene expression
  • Neutrophil degranulation
  • Fatty acyl-CoA biosynthesis
  • Neddylation
  • Antigen processing: Ubiquitination & Proteasome degradation
ACTA1 and HDAC4 actin alpha 1, skeletal muscle histone deacetylase 4
  • Striated Muscle Contraction
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • Notch-HLH transcription pathway
  • SUMOylation of intracellular receptors
  • SUMOylation of chromatin organization proteins
  • RUNX2 regulates chondrocyte maturation
  • RUNX3 regulates p14-ARF
  • Latrunculin A
  • Sucrose
  • Ulapualide A
  • Kabiramide C
  • Jaspisamide A
  • Tmr
  • 4-Methyl-Histidine
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • Aplyronine A
  • Reidispongiolide A
  • Reidispongiolide C
  • Sphinxolide B
  • LATRUNCULIN B
  • Zinc
  • Belinostat
  • Romidepsin
  • Panobinostat
  • N-hydroxy-5-[(3-phenyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)carbonyl]thiophene-2-carboxamide
  • 2,2,2-TRIFLUORO-1-{5-[(3-PHENYL-5,6-DIHYDROIMIDAZO[1,2-A]PYRAZIN-7(8H)-YL)CARBONYL]THIOPHEN-2-YL}ETHANE-1,1-DIOL
  • Congenital fiber type disproportion (CFTD)
  • Cap myopathy
  • Nemaline myopathy
  • Brachydacytly-mental retardation syndrome and Smith-Magenis syndrome
ACTA1 and MAPT actin alpha 1, skeletal muscle microtubule associated protein tau
  • Striated Muscle Contraction
  • Caspase-mediated cleavage of cytoskeletal proteins
  • Latrunculin A
  • Sucrose
  • Ulapualide A
  • Kabiramide C
  • Jaspisamide A
  • Tmr
  • 4-Methyl-Histidine
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • Aplyronine A
  • Reidispongiolide A
  • Reidispongiolide C
  • Sphinxolide B
  • LATRUNCULIN B
  • Lansoprazole
  • Astemizole
  • Paclitaxel
  • Docetaxel
  • Congenital fiber type disproportion (CFTD)
  • Cap myopathy
  • Nemaline myopathy
  • Amyotrophic lateral sclerosis (ALS); Lou Gehrig's disease
  • Frontotemporal lobar degeneration (FTLD), including: Pick disease of brain; Frontotemporal dementia (FTD); Ubiquitin-positive frontotemporal dementia (UP-FTD); Progressive supranuclear palsy type 1 (PSNP1); Inclusion body myopathy with early-onset paget disease and frontotemporal dementia (IBMPFD); Frontotemporal dementia, chromosome 3-linked (FTD3)
  • Progressive supranuclear palsy (PSP); Steele-Richardson-Olszewski syndrome
ACTA1 and MYO10 actin alpha 1, skeletal muscle myosin X
  • Striated Muscle Contraction
  • Regulation of actin dynamics for phagocytic cup formation
  • Netrin-1 signaling
  • FCGR3A-mediated phagocytosis
  • Latrunculin A
  • Sucrose
  • Ulapualide A
  • Kabiramide C
  • Jaspisamide A
  • Tmr
  • 4-Methyl-Histidine
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • Aplyronine A
  • Reidispongiolide A
  • Reidispongiolide C
  • Sphinxolide B
  • LATRUNCULIN B
  • Congenital fiber type disproportion (CFTD)
  • Cap myopathy
  • Nemaline myopathy
ACTA1 and MACF1 actin alpha 1, skeletal muscle microtubule actin crosslinking factor 1
  • Striated Muscle Contraction
  • Latrunculin A
  • Sucrose
  • Ulapualide A
  • Kabiramide C
  • Jaspisamide A
  • Tmr
  • 4-Methyl-Histidine
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • Aplyronine A
  • Reidispongiolide A
  • Reidispongiolide C
  • Sphinxolide B
  • LATRUNCULIN B
  • Congenital fiber type disproportion (CFTD)
  • Cap myopathy
  • Nemaline myopathy
ACTB and MAPT actin beta microtubule associated protein tau
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • Gap junction degradation
  • Formation of annular gap junctions
  • Regulation of actin dynamics for phagocytic cup formation
  • Regulation of actin dynamics for phagocytic cup formation
  • HATs acetylate histones
  • Prefoldin mediated transfer of substrate to CCT/TriC
  • Folding of actin by CCT/TriC
  • EPHB-mediated forward signaling
  • EPH-ephrin mediated repulsion of cells
  • Adherens junctions interactions
  • Adherens junctions interactions
  • Recycling pathway of L1
  • Recycling pathway of L1
  • VEGFA-VEGFR2 Pathway
  • Interaction between L1 and Ankyrins
  • Interaction between L1 and Ankyrins
  • Cell-extracellular matrix interactions
  • B-WICH complex positively regulates rRNA expression
  • RHO GTPases activate IQGAPs
  • RHO GTPases Activate WASPs and WAVEs
  • RHO GTPases Activate WASPs and WAVEs
  • RHO GTPases Activate Formins
  • RHO GTPases Activate Formins
  • MAP2K and MAPK activation
  • UCH proteinases
  • DNA Damage Recognition in GG-NER
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Clathrin-mediated endocytosis
  • Signaling downstream of RAS mutants
  • FCGR3A-mediated phagocytosis
  • FCGR3A-mediated phagocytosis
  • Factors involved in megakaryocyte development and platelet production
  • Caspase-mediated cleavage of cytoskeletal proteins
  • Quercetin
  • Phenethyl Isothiocyanate
  • Lansoprazole
  • Astemizole
  • Paclitaxel
  • Docetaxel
  • Other phagocyte defects, including the following eight diseases: Chediak-Higashi syndrome; Griscelli syndrome, type 1 (GS1); Griscelli syndrome, type 2 (GS2); Griscelli syndrome, type 3 (GS3); beta-actin deficiency; Neutrophil-specific granule deficiency; Myeloperoxidase deficiency; Glucose 6-phosphate dehydrogenase deficiency; Shwachman syndrome
  • Amyotrophic lateral sclerosis (ALS); Lou Gehrig's disease
  • Frontotemporal lobar degeneration (FTLD), including: Pick disease of brain; Frontotemporal dementia (FTD); Ubiquitin-positive frontotemporal dementia (UP-FTD); Progressive supranuclear palsy type 1 (PSNP1); Inclusion body myopathy with early-onset paget disease and frontotemporal dementia (IBMPFD); Frontotemporal dementia, chromosome 3-linked (FTD3)
  • Progressive supranuclear palsy (PSP); Steele-Richardson-Olszewski syndrome
ACTB and P2RX7 actin beta purinergic receptor P2X 7
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • Gap junction degradation
  • Formation of annular gap junctions
  • Regulation of actin dynamics for phagocytic cup formation
  • Regulation of actin dynamics for phagocytic cup formation
  • HATs acetylate histones
  • Prefoldin mediated transfer of substrate to CCT/TriC
  • Folding of actin by CCT/TriC
  • EPHB-mediated forward signaling
  • EPH-ephrin mediated repulsion of cells
  • Adherens junctions interactions
  • Adherens junctions interactions
  • Recycling pathway of L1
  • Recycling pathway of L1
  • VEGFA-VEGFR2 Pathway
  • Interaction between L1 and Ankyrins
  • Interaction between L1 and Ankyrins
  • Cell-extracellular matrix interactions
  • B-WICH complex positively regulates rRNA expression
  • RHO GTPases activate IQGAPs
  • RHO GTPases Activate WASPs and WAVEs
  • RHO GTPases Activate WASPs and WAVEs
  • RHO GTPases Activate Formins
  • RHO GTPases Activate Formins
  • MAP2K and MAPK activation
  • UCH proteinases
  • DNA Damage Recognition in GG-NER
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Clathrin-mediated endocytosis
  • Signaling downstream of RAS mutants
  • FCGR3A-mediated phagocytosis
  • FCGR3A-mediated phagocytosis
  • Factors involved in megakaryocyte development and platelet production
  • Elevation of cytosolic Ca2+ levels
  • Platelet homeostasis
  • The NLRP3 inflammasome
  • The NLRP3 inflammasome
  • Purinergic signaling in leishmaniasis infection
  • Quercetin
  • Phenethyl Isothiocyanate
  • Other phagocyte defects, including the following eight diseases: Chediak-Higashi syndrome; Griscelli syndrome, type 1 (GS1); Griscelli syndrome, type 2 (GS2); Griscelli syndrome, type 3 (GS3); beta-actin deficiency; Neutrophil-specific granule deficiency; Myeloperoxidase deficiency; Glucose 6-phosphate dehydrogenase deficiency; Shwachman syndrome

Page 10 out of 266 pages